<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1646-2122</journal-id>
<journal-title><![CDATA[Revista Portuguesa de Ortopedia e Traumatologia]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Port. Ortop. Traum.]]></abbrev-journal-title>
<issn>1646-2122</issn>
<publisher>
<publisher-name><![CDATA[Sociedade Portuguesa de Ortopedia e Traumatologia]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1646-21222013000300003</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[Aplicação de fatores de crescimento no tratamento de lesões musculotendinosas: Solução ou Ilusão?]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ferrão]]></surname>
<given-names><![CDATA[Ana]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gutierres]]></surname>
<given-names><![CDATA[Manuel]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
<xref ref-type="aff" rid="A02"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Centro Hospitalar de São João Serviço de Ortopedia e Traumatologia ]]></institution>
<addr-line><![CDATA[Porto ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="A02">
<institution><![CDATA[,Universidade do Porto Faculdade de Medicina ]]></institution>
<addr-line><![CDATA[Porto ]]></addr-line>
<country>Portugal</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2013</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2013</year>
</pub-date>
<volume>21</volume>
<numero>3</numero>
<fpage>259</fpage>
<lpage>270</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_arttext&amp;pid=S1646-21222013000300003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_abstract&amp;pid=S1646-21222013000300003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_pdf&amp;pid=S1646-21222013000300003&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Objetivo: As lesões tendinosas e musculares são muito frequentes em desportistas, existindo uma intensa investigação para encontrar novas formas de tratamento que permitam uma recuperação mais precoce. Justifica-se assim o interesse pelas terapias com fatores de crescimento, com o objetivo de acelerar a cicatrização tecidular. O plasma rico em plaquetas (ou plasma rico em fatores de crescimento) é uma fração do sangue autólogo obtida por centrifugação, com uma concentração plaquetária superior à fisiológica. O objetivo desta revisão é avaliar a repercussão clínica e/ou imagiológica desta terapia no tratamento das tendinopatias mais frequentes (rotulianas, aquilianas, do cotovelo e da coifa dos rotadores) e nas lesões musculares. Pretendemos também analisar eventuais efeitos adversos e a possível influência de fatores externos. Fontes dos dados: Foram incluídos 62 artigos, entre 2004 e 2012 sobre plasma rico em plaquetas ou a sua aplicação nas lesões musculares e/ou tendinosas. Síntese dos dados: O plasma rico em plaquetas é eficaz no tratamento das epicondiloses e tendinopatias rotulianas, o mesmo não sucedendo nas tendinopatias crónicas do Aquiles. Também ao nível da coifa dos rotadores, esta aplicação não parece ser muito benéfica, apenas tendo algum impacto na diminuição da dor e na prevenção das recidivas pós-operatórias. Nas lesões musculares, os poucos estudos encontrados parecem confirmar um efeito positivo desta terapia. Conclusões: É possível que os diferentes resultados observados se devam à não uniformização dos protocolos de preparação e aplicação do plasma rico em plaquetas. Em estudos futuros é necessário padronizar estes parâmetros de modo a maximizar o efeito terapêutico.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Background: Muscle and tendon injuries are very common in athletes and there is an intensive research to find new treatments that allow an earlier recovery. This justifies the interest in therapies with growth factors, with the aim of accelerate the tissue healing. The platelet-rich plasma (or plasma rich in growth factors) is a fraction of autologous blood obtained by centrifugation, with a platelet concentration higher than the physiological. The aim of this review is to evaluate the clinical and/or imaging outcomes of this therapy in the treatment of the most frequent tendinopathies (patellar, Achilles, rotator cuff and elbow tendinopathies) and in muscle injuries. We also intend to analyze the potential side effects and the possible influence of external factors. Material and Methods: We included 62 articles between 2004 and 2012 on platelet-rich plasma or on its application in muscle and/or tendon injuries. results: Platelet-rich plasma is effective in treating epicondylosis and patellar tendinopathies, but the same doesn’t happen in chronic Achilles tendinopathies. In the rotator cuff, this application also does not seem to be very beneficial, just having some impact in reducing the pain and in the prevention of postoperative recurrence. In muscle injuries, the few studies found seem to confirm a positive effect of this therapy. Discussion and Conclusion: It’s possible that the different outcomes observed are due to the nonstandardization of platelet-rich plasma preparation and application protocols. In future studies these parameters need to be standardized in order to maximize the therapeutic effect.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[Plasma rico em plaquetas]]></kwd>
<kwd lng="pt"><![CDATA[fatores de crescimento]]></kwd>
<kwd lng="pt"><![CDATA[tendinopatias]]></kwd>
<kwd lng="pt"><![CDATA[lesões musculares]]></kwd>
<kwd lng="en"><![CDATA[Platelet-rich plasma]]></kwd>
<kwd lng="en"><![CDATA[growth factors]]></kwd>
<kwd lng="en"><![CDATA[tendinopathies]]></kwd>
<kwd lng="en"><![CDATA[muscle injuries]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[ <p align="right"><b><font face="Verdana" size="2">ARTIGO DE REVISÃO</font></b></p>    <p>&nbsp;</p>    <p><b><font face="Verdana" size="4">Aplicação de fatores de crescimento no tratamento de lesões musculotendinosas. Solução ou Ilusão?</font></b></p>    <p>&nbsp;</p>    <p><font face="Verdana" size="2"><b>Ana Ferrão<sup>I, II</sup></b>; <b>Manuel Gutierres<sup>I, II</sup></b></font></p>    <p><font face="Verdana" size="2">I. Serviço de Ortopedia e Traumatologia. Centro Hospitalar de São João. Porto. Portugal.<br />II. Faculdade de Medicina da Universidade do Porto. Porto. Portugal.<br /></font></p>    <p>&nbsp;</p>    <p><font face="Verdana" size="2"><a name="topc"></a><a href="#c">Endereço para correspondência</a></font></p>    <p>&nbsp;</p>    <p><b><font face="Verdana" size="2">RESUMO</font></b></p><font face="verdana" size="2">    ]]></body>
<body><![CDATA[<p>Objetivo: As les&otilde;es tendinosas e musculares s&atilde;o muito frequentes em desportistas, existindo uma intensa investiga&ccedil;&atilde;o para encontrar novas formas de tratamento que permitam uma recupera&ccedil;&atilde;o mais precoce. Justifica-se assim o interesse pelas terapias com fatores de crescimento, com o objetivo de acelerar a cicatriza&ccedil;&atilde;o tecidular. O plasma rico em plaquetas (ou plasma rico em fatores de crescimento) &eacute; uma fra&ccedil;&atilde;o do sangue aut&oacute;logo obtida por centrifuga&ccedil;&atilde;o, com uma concentra&ccedil;&atilde;o plaquet&aacute;ria superior &agrave; fisiol&oacute;gica. O objetivo desta revis&atilde;o &eacute; avaliar a repercuss&atilde;o cl&iacute;nica e/ou imagiol&oacute;gica desta terapia no tratamento das tendinopatias mais frequentes (rotulianas, aquilianas, do cotovelo e da coifa dos rotadores) e nas les&otilde;es musculares. Pretendemos tamb&eacute;m analisar eventuais efeitos adversos e a poss&iacute;vel influ&ecirc;ncia de fatores externos.</p>     <p>Fontes dos dados: Foram inclu&iacute;dos 62 artigos, entre 2004 e 2012 sobre plasma rico em plaquetas ou a sua aplica&ccedil;&atilde;o nas les&otilde;es musculares e/ou tendinosas.</p>     <p>S&iacute;ntese dos dados: O plasma rico em plaquetas &eacute; eficaz no tratamento das epicondiloses e tendinopatias rotulianas, o mesmo n&atilde;o sucedendo nas tendinopatias cr&oacute;nicas do Aquiles. Tamb&eacute;m ao n&iacute;vel da coifa dos rotadores, esta aplica&ccedil;&atilde;o n&atilde;o parece ser muito ben&eacute;fica, apenas tendo algum impacto na diminui&ccedil;&atilde;o da dor e na preven&ccedil;&atilde;o das recidivas p&oacute;s-operat&oacute;rias. Nas les&otilde;es musculares, os poucos estudos encontrados parecem confirmar um efeito positivo desta terapia.</p>     <p>Conclus&otilde;es: &Eacute; poss&iacute;vel que os diferentes resultados observados se devam &agrave; n&atilde;o uniformiza&ccedil;&atilde;o dos protocolos de prepara&ccedil;&atilde;o e aplica&ccedil;&atilde;o do plasma rico em plaquetas. Em estudos futuros &eacute; necess&aacute;rio padronizar estes par&acirc;metros de modo a maximizar o efeito terap&ecirc;utico.</p></font>    <p><font face="verdana" size="2"><b>Palavras chave</b>: Plasma rico em plaquetas, fatores de crescimento, tendinopatias, lesões musculares. </font></p>    <p>&nbsp;</p>    <p><b><font face="Verdana" size="2">ABSTRACT</font></b></p><font face="verdana" size="2">    <p>Background: Muscle and tendon injuries are very common in athletes and there is an intensive research to&nbsp;find new treatments that allow an earlier recovery. This justifies the interest in therapies with growth factors,&nbsp;with the aim of accelerate the tissue healing. The platelet-rich plasma (or plasma rich in growth factors)&nbsp;is a fraction of autologous blood obtained by centrifugation, with a platelet concentration higher than the&nbsp;physiological. The aim of this review is to evaluate the clinical and/or imaging outcomes of this therapy in&nbsp;the treatment of the most frequent tendinopathies (patellar, Achilles, rotator cuff and elbow tendinopathies)&nbsp;and in muscle injuries. We also intend to analyze the potential side effects and the possible influence of&nbsp;external factors.&nbsp;</p>     <p>Material and Methods: We included 62 articles between 2004 and 2012 on platelet-rich plasma or on its&nbsp;application in muscle and/or tendon injuries.&nbsp;</p>     <p>results: Platelet-rich plasma is effective in treating epicondylosis and patellar tendinopathies, but the same&nbsp;doesn&rsquo;t happen in chronic Achilles tendinopathies. In the rotator cuff, this application also does not seem&nbsp;to be very beneficial, just having some impact in reducing the pain and in the prevention of postoperative&nbsp;recurrence. In muscle injuries, the few studies found seem to confirm a positive effect of this therapy.&nbsp;</p>     ]]></body>
<body><![CDATA[<p>Discussion and Conclusion: It&rsquo;s possible that the different outcomes observed are due to the nonstandardization&nbsp;of platelet-rich plasma preparation and application protocols. In future studies these&nbsp;parameters need to be standardized in order to maximize the therapeutic effect.</p></font>    <p><font face="verdana" size="2"><b>Key words</b>: Platelet-rich plasma, growth factors, tendinopathies, muscle injuries. </font></p>    <p>&nbsp;</p>    <p><b><font face="Verdana" size="2">INTRODUÇÃO</font></b></p><font face="verdana" size="2">    <p>As les&otilde;es tendinosas s&atilde;o frequentes em adultos jovens e de meia-idade[1]. Segundo a literatura, tendinopatia &eacute; o termo usado para designar a tr&iacute;ade de dor, edema e disfun&ccedil;&atilde;o[2-4], incluindo: tendinites, tendinoses e ruturas[5]. As tendinoses s&atilde;o muito frequentes nos desportistas recreativos[6, 7]; j&aacute; as ruturas s&atilde;o comuns na alta competi&ccedil;&atilde;o, ocorrendo por traumatismo agudo ou em tend&otilde;es cronicamente lesados[5, 8]. A hipovasculariza&ccedil;&atilde;o dos tend&otilde;es condiciona a sua lenta cicatriza&ccedil;&atilde;o[3, 7, 9, 10], dificultando o tratamento conservador. <br />As les&otilde;es musculares tamb&eacute;m s&atilde;o comuns em atletas[11, 12], podendo ser causadas por contus&atilde;o, estiramento ou lacera&ccedil;&atilde;o[5, 13], sendo as duas primeiras as mais frequentes[12, 13]. A maioria &eacute; tratada conservadoramente[14] e recorrendo a anti-inflamat&oacute;rios n&atilde;o esteroides ap&oacute;s a fase aguda, embora estes f&aacute;rmacos possam prejudicar a cicatriza&ccedil;&atilde;o muscular[5, 13]. <br />Da procura de novas op&ccedil;&otilde;es de tratamento, que permitam um retorno precoce &agrave; atividade com menores taxas de recidiva, surgiu o interesse pela aplica&ccedil;&atilde;o das terapias com fatores de crescimento[2, 4]. O Plasma Rico em Plaquetas (PRP) define-se como &ldquo;uma fra&ccedil;&atilde;o do sangue aut&oacute;logo, que possui uma concentra&ccedil;&atilde;o de plaquetas acima do valor normal&rdquo;[4]. A maioria dos autores admite um valor de 1,000,000 plaquetas/&micro;L como defini&ccedil;&atilde;o, correspondendo a uma concentra&ccedil;&atilde;o 2,5 a 8 vezes superior &agrave; fisiol&oacute;gica[6, 10, 12]. <br />As primeiras descri&ccedil;&otilde;es desta terapia remontam aos anos 90[4, 9, 15], sendo aplicada na Medicina Desportiva desde 2003[16].<br />Nas fases iniciais, a introdu&ccedil;&atilde;o de fatores de crescimento pode estimular a cicatriza&ccedil;&atilde;o fisiol&oacute;gica [9]. &Eacute; bem conhecido o papel das plaquetas, atrav&eacute;s da liberta&ccedil;&atilde;o de gr&acirc;nulos alfa que cont&ecirc;m fatores de crescimento[17, 18]. Estas prepara&ccedil;&otilde;es s&atilde;o vantajosas por conterem mol&eacute;culas com diferentes a&ccedil;&otilde;es e em concentra&ccedil;&otilde;es fisiol&oacute;gicas, mimetizando ao m&aacute;ximo a secre&ccedil;&atilde;o normal[18-20]. As principais mol&eacute;culas presentes no PRP e envolvidas na cicatriza&ccedil;&atilde;o s&atilde;o referidas na <a href="#q1">Quadro I</a>.<br />    <p>&nbsp;</p>    <p>    <center><a name="q1"></a><img src="/img/revistas/rpot/v21n3/21n3a02q1.jpg"></center></p>    
<p>&nbsp;</p>A t&eacute;cnica de prepara&ccedil;&atilde;o do PRP implica a aspira&ccedil;&atilde;o de sangue perif&eacute;rico, seguida de centrifuga&ccedil;&atilde;o[4, 9, 21]. Est&atilde;o descritos diversos protocolos com diferen&ccedil;as na concentra&ccedil;&atilde;o de plaquetas[22], tipo de anticoagulantes[19], percentagem de leuc&oacute;citos[9] e modo de ativa&ccedil;&atilde;o (com trombina, c&aacute;lcio ou colag&eacute;nio sol&uacute;vel)[4, 19]. Ap&oacute;s prepara&ccedil;&atilde;o, o PRP pode ser aplicado nas 8 horas seguintes[19]. A dose[19, 23], a dura&ccedil;&atilde;o da aplica&ccedil;&atilde;o[19] e a idade[24, 25] podem influenciar o efeito terap&ecirc;utico. <br />Na literatura surgem diferentes designa&ccedil;&otilde;es consoante o protocolo usado, contudo o produto final encaixa-se geralmente em um destes tipos: plasma rico em plaquetas, puro ou com leuc&oacute;citos; fibrina rica em plaquetas, pura ou com leuc&oacute;citos[12, 26, 27]. As matrizes de fibrina formam-se por polimeriza&ccedil;&atilde;o do PRP, permitindo a liberta&ccedil;&atilde;o gradual dos fatores de crescimento[4, 7, 28] e a ancoragem de c&eacute;lulas[4]. <br />O PRP pode ser aplicado por inje&ccedil;&atilde;o ou como adjuvante &agrave; cirurgia[4, 21]. De acordo com as Guidelines da Associa&ccedil;&atilde;o Americana de Cirurgi&otilde;es Ortop&eacute;dicos[29], deve evitar-se o uso de anti-inflamat&oacute;rios n&atilde;o esteroides 1-2 semanas antes e at&eacute; 2 semanas ap&oacute;s o tratamento[12, 21, 29]; e est&atilde;o contraindicados os corticosteroides nas 2-3 semanas e os anticoagulantes nos 5 dias que precedem a inje&ccedil;&atilde;o[29]. A maioria dos autores aconselha a inje&ccedil;&atilde;o guiada por ecografia[4, 21, 29], na regi&atilde;o intra ou peri-lesional[4]. Ap&oacute;s a interven&ccedil;&atilde;o, recomenda-se repouso, gelo, compress&atilde;o e eleva&ccedil;&atilde;o, por 48 horas[4]; com in&iacute;cio precoce de fisioterapia[12]. Caso existam sinais de inflama&ccedil;&atilde;o local, hist&oacute;ria de neoplasias, altera&ccedil;&otilde;es hematol&oacute;gicas, septic&eacute;mia ou febre, o PRP est&aacute; contraindicado[12, 21, 29].<br />Est&atilde;o descritos os efeitos angiog&eacute;nicos[4], mitog&eacute;nicos[4], analg&eacute;sicos[9], anti-inflamat&oacute;rios, antibacterianos[4, 9, 20] e hemost&aacute;ticos[9] do PRP. Tamb&eacute;m &eacute; reconhecido o seu papel na cicatriza&ccedil;&atilde;o de feridas[9]. Alguns dados sugerem tamb&eacute;m um efeito protetor sobre condr&oacute;citos[9, 25] e ten&oacute;citos[30]. Na Ortopedia &eacute; usado no tratamento de v&aacute;rias les&otilde;es musculosquel&eacute;ticas[4, 20]. <br />&Eacute; consensual que o PRP &eacute; uma terapia segura, nunca tendo sido descritos efeitos sist&eacute;micos[4, 18, 31, 32]. Entre os efeitos adversos potenciais incluem-se fibrose, infe&ccedil;&atilde;o e carcinog&eacute;nese[4, 18]. A hemorragia, les&atilde;o dos tecidos e dor s&atilde;o complica&ccedil;&otilde;es frequentes[12].<br />O estudo da aplica&ccedil;&atilde;o cl&iacute;nica do PRP nas les&otilde;es musculares &eacute; ainda muito pouco desenvolvido. Nas les&otilde;es tendinosas a literatura &eacute; vasta em estudos animais e cient&iacute;ficos, sendo question&aacute;vel a sua extrapola&ccedil;&atilde;o para os humanos[4, 18]. As les&otilde;es mais estudadas neste contexto s&atilde;o as tendinopatias rotulianas, aquilianas, da coifa dos rotadores e do cotovelo.<br />O objetivo desta revis&atilde;o &eacute; avaliar a repercuss&atilde;o cl&iacute;nica e/ou imagiol&oacute;gica da aplica&ccedil;&atilde;o de prepara&ccedil;&otilde;es ricas em fatores de crescimento no tratamento das tendinopatias mais estudadas nesta &aacute;rea, abordando tamb&eacute;m a sua aplica&ccedil;&atilde;o nas les&otilde;es musculares. Adicionalmente pretendemos analisar os efeitos adversos e a influ&ecirc;ncia de fatores externos, de modo a poder inferir sobre a efic&aacute;cia deste m&eacute;todo.</p></font>    <p>&nbsp;</p>    ]]></body>
<body><![CDATA[<p><b><font face="Verdana" size="2">MÉTODOS</font></b></p><font face="verdana" size="2">    <p>Procedeu-se &agrave; pesquisa de artigos utilizando a base de dados MEDLINE, via PubMed, usando como palavra-chave &ldquo;platelet-rich plasma&rdquo; isoladamente e em combina&ccedil;&atilde;o com os termos &ldquo;tendinopathies&rdquo; e &ldquo;muscle injuries&rdquo;. Numa segunda fase, as listas bibliogr&aacute;ficas de todos os estudos inclu&iacute;dos foram manualmente revistas, sendo adicionados mais seis artigos. A pesquisa foi restrita a artigos em ingl&ecirc;s, portugu&ecirc;s e espanhol; e limitada entre 2006 e 2012, tendo-se inclu&iacute;do um artigo de 2004 pela sua relev&acirc;ncia. <br />Foram encontrados 75 artigos sobre plasma rico em plaquetas ou sobre a sua aplica&ccedil;&atilde;o nas les&otilde;es musculares e/ou tendinosas, dos quais (ap&oacute;s leitura integral) apenas 62 foram inclu&iacute;dos.</p></font>    <p>&nbsp;</p>    <p><b><font face="Verdana" size="2">RESULTADOS</font></b></p><font face="verdana" size="2">    <p>Na maioria dos estudos, a an&aacute;lise dos resultados foi feita atrav&eacute;s de question&aacute;rios de avalia&ccedil;&atilde;o funcional e da imagiologia.</p></font>    <p><b><font face="Verdana" size="2">Lesões musculares</font></b></p><font face="verdana" size="2">    <p>Foram inclu&iacute;dos quatro estudos de aplica&ccedil;&atilde;o do PRP nas les&otilde;es musculares.<br />Um estudo piloto comparou a aplica&ccedil;&atilde;o de m&uacute;ltiplas inje&ccedil;&otilde;es (m&eacute;dia de 5.4) de soro condicionado aut&oacute;logo com inje&ccedil;&otilde;es de Traumeel&reg;+Actovegin&reg; (m&eacute;dia de 8.3), no tratamento de distens&otilde;es musculares do membro inferior[13]. Os resultados favoreceram o grupo submetido ao soro condicionado aut&oacute;logo, com um tempo de retorno &agrave; competi&ccedil;&atilde;o significativamente inferior (16.6 dias versus 22.3 dias no grupo controlo) e resolu&ccedil;&atilde;o imagiol&oacute;gica precoce do edema/hemorragia[13]. <br />O tratamento da rotura aguda do adutor longo com tr&ecirc;s inje&ccedil;&otilde;es semanais de PRP obteve al&iacute;vio da dor, resolu&ccedil;&atilde;o imagiol&oacute;gica e retorno &agrave; competi&ccedil;&atilde;o sete dias ap&oacute;s o final do tratamento [24]. O tratamento da distens&atilde;o aguda do semimembranoso com uma inje&ccedil;&atilde;o de PRP tamb&eacute;m se associou a bons resultados cl&iacute;nicos, funcionais e imagiol&oacute;gicos, ap&oacute;s 17 dias[33]. &nbsp;<br />S&aacute;nchez et al relataram a aplica&ccedil;&atilde;o de PRP em futebolistas profissionais com les&otilde;es musculares, resultando em melhoria cl&iacute;nica e funcional em metade do tempo esperado, com resolu&ccedil;&atilde;o imagiol&oacute;gica total[34]. As roturas pequenas tiveram uma evolu&ccedil;&atilde;o favor&aacute;vel com uma &uacute;nica inje&ccedil;&atilde;o; j&aacute; nas roturas de m&eacute;dia ou grande dimens&atilde;o foram necess&aacute;rios dois ou tr&ecirc;s tratamentos semanais[34].</p></font>    <p><b><font face="Verdana" size="2">Lesões tendinosas</font></b></p><font face="verdana" size="2">    <p>O estudo da aplica&ccedil;&atilde;o de PRP nas les&otilde;es tendinosas est&aacute; bem documentado, tendo-se inclu&iacute;do 26 artigos. <br />Tendinopatias do Cotovelo<br />Foram encontrados seis estudos relativos &agrave; aplica&ccedil;&atilde;o de PRP nas tendinopatias do cotovelo, todas elas de evolu&ccedil;&atilde;o cr&oacute;nica[35-40] (<a href="/img/revistas/rpot/v21n3/21n3a02q2.jpg">Quadro II</a>). <br />    
<p>&nbsp;</p>    ]]></body>
<body><![CDATA[<p>    <center><a href="/img/revistas/rpot/v21n3/21n3a02q2.jpg">Quadro II</a></center></p>    
<p>&nbsp;</p>Um estudo avaliou a capacidade angiog&eacute;nica do PRP aos seis meses, revelando uma melhoria da morfologia do tend&atilde;o e aumento da vasculariza&ccedil;&atilde;o na regi&atilde;o miotendinosa, embora n&atilde;o significativos[39].<br />Tendinopatias dos Rotadores da Coifa<br />Inclu&iacute;ram-se seis artigos relativamente &agrave; aplica&ccedil;&atilde;o de PRP nas tendinopatias dos rotadores da coifa[41-46], sendo os resultados muito divergentes (<a href="/img/revistas/rpot/v21n3/21n3a02q3.jpg">Quadro III</a>).<br />    
<p>&nbsp;</p>    <p>    <center><a href="/img/revistas/rpot/v21n3/21n3a02q3.jpg">Quadro III</a></center></p>    
<p>&nbsp;</p>Existem tamb&eacute;m relatos de sucesso na aplica&ccedil;&atilde;o de membranas de fibrina durante a repara&ccedil;&atilde;o artrosc&oacute;pica de uma rotura do supraespinhoso[47] e na tendinite calcificante desse mesmo tend&atilde;o[48].<br />Tendinopatias Aquilianas<br />Um total de seis estudos foram inclu&iacute;dos nos quais se aplicou PRP nas tendinopatias Aquilianas[49-54] (<a href="/img/revistas/rpot/v21n3/21n3a02q4.jpg">Quadro IV</a>). <br />    
<p>&nbsp;</p>    <p>    <center><a href="/img/revistas/rpot/v21n3/21n3a02q4.jpg">Quadro IV</a></center></p>    
]]></body>
<body><![CDATA[<p>&nbsp;</p>Apenas se observou um efeito ben&eacute;fico do PRP em dois dos estudos: no tratamento das roturas do Aquiles[49] e nas tendinopatias cr&oacute;nicas[54]. Contrariando estes dados, h&aacute; descri&ccedil;&otilde;es da aplica&ccedil;&atilde;o de m&uacute;ltiplas inje&ccedil;&otilde;es de PRP no tratamento de roturas agudas do Aquiles, resultando em repara&ccedil;&atilde;o acelerada do tend&atilde;o confirmada clinica e imagiologicamente[8]. A aplica&ccedil;&atilde;o de prepara&ccedil;&otilde;es ricas em fatores de crescimento no tratamento de complica&ccedil;&otilde;es p&oacute;s-cir&uacute;rgicas do Aquiles tamb&eacute;m obteve resultados funcionais satisfat&oacute;rios[55]. <br />Tendinopatias do Rotuliano <br />Inclu&iacute;ram-se quatro estudos com a aplica&ccedil;&atilde;o do PRP nas tendinopatias rotulianas. <br />Dois ensaios cl&iacute;nicos avaliaram a aplica&ccedil;&atilde;o de PRP na cicatriza&ccedil;&atilde;o das &aacute;reas dadoras de enxertos para reconstru&ccedil;&atilde;o do ligamento cruzado anterior[56, 57]. Num deles, ap&oacute;s seis meses, a administra&ccedil;&atilde;o de PRP resultou em menor &aacute;rea de tend&atilde;o n&atilde;o regenerada e menos dor, comparativamente aos controlos[56]. No outro estudo, aos 12 meses apenas a avalia&ccedil;&atilde;o funcional se mostrou significativamente superior no grupo submetido ao PRP[57].<br />Dois estudos testaram o tratamento da tendinose rotuliana com tr&ecirc;s inje&ccedil;&otilde;es quinzenais de PRP[58, 59]. Aos seis meses, verificou-se uma melhoria significativa do estado de sa&uacute;de e da atividade f&iacute;sica, com retorno ao desporto dois meses ap&oacute;s o final do tratamento[58]. Comparando a aplica&ccedil;&atilde;o de PRP com a fisioterapia, observou-se apenas uma vantagem significativa do PRP no n&iacute;vel de atividade desportiva[59].</p></font>    <p><b><font face="Verdana" size="2">Complicações</font></b></p><font face="verdana" size="2">    <p>Em 14 dos estudos nenhuma rea&ccedil;&atilde;o adversa foi reportada[8, 13, 24, 33, 43, 44, 46, 47, 49, 50, 52, 56, 57, 59]. Nos restantes foram apenas descritas rea&ccedil;&otilde;es inflamat&oacute;rias localizadas: dor moderada (dura&ccedil;&atilde;o entre um dia e quatro semanas)[36, 37, 40, 42, 58]; dor associada a rigidez[58]; s&iacute;ndrome dolorosa regional complexa (tardia)[54] e infe&ccedil;&atilde;o profunda[53].</p></font>    <p>&nbsp;</p>    <p><b><font face="Verdana" size="2">DISCUSSÃO</font></b></p><font face="verdana" size="2">    <p>Com exce&ccedil;&atilde;o das tendinopatias do cotovelo, em geral, os estudos de maior qualidade t&ecirc;m resultados menos animadores. O PRP parece mais eficaz no tratamento das epicondiloses, com resultados insatisfat&oacute;rios nas tendinopatias Aquilianas.<br />Alguns autores explicam estas diverg&ecirc;ncias alegando que existem diferen&ccedil;as entre os mecanismos de repara&ccedil;&atilde;o dos tend&otilde;es associados ao suporte do peso e dos n&atilde;o sujeitos a essa carga[2, 6, 16] e entre os tend&otilde;es sinoviais e extrassinoviais[60]. A concentra&ccedil;&atilde;o de plaquetas parece tamb&eacute;m ser um fator determinante, sendo o benef&iacute;cio cl&iacute;nico atingido com aumentos de cerca de quatro vezes na sua concentra&ccedil;&atilde;o[10]; aumentos superiores podem ter um efeito inibit&oacute;rio, enquanto as concentra&ccedil;&otilde;es inferiores s&atilde;o subterap&ecirc;uticas[9]. Contudo, um estudo recente reportou aus&ecirc;ncia de efeitos inibit&oacute;rios com concentra&ccedil;&otilde;es 50 vezes superiores &agrave;s fisiol&oacute;gicas[61], permanecendo desconhecida a concentra&ccedil;&atilde;o &oacute;tima de plaquetas[23]. A percentagem de leuc&oacute;citos &eacute; tamb&eacute;m um tema controverso, com a maioria dos autores a favor da sua exclus&atilde;o[9, 17, 20, 21, 45], embora alguns defendam o seu papel antimicrobiano [4, 27, 28] e anti-inflamat&oacute;rio[25, 27]. Os anest&eacute;sicos locais podem tamb&eacute;m influenciar os resultados[4].<br />Na maioria das tendinopatias os fen&oacute;menos inflamat&oacute;rios s&atilde;o m&iacute;nimos ou ausentes, nem sempre se justificando o tratamento com anti-inflamat&oacute;rios[50]. Os corticosteroides (outrora o gold-standard da terapia) t&ecirc;m bons resultados a curto prazo, mas a longo prazo aumentam o risco de rotura[1, 30]. A abordagem atual passa pelos programas de treino exc&ecirc;ntrico, obtendo-se resultados satisfat&oacute;rios[2, 50].<br />A aplica&ccedil;&atilde;o do PRP foi bem-sucedida nas epicondiloses, com melhorias cl&iacute;nicas e funcionais significativas a longo prazo; mostrando-se superiores aos anest&eacute;sicos locais[35] e aos corticosteroides[36, 37] e equivalentes ao sangue aut&oacute;logo[38, 40]. A superioridade dos corticosteroides manteve-se at&eacute; &agrave;s 12 semanas, sendo o PRP superior a longo prazo[36, 37]. Considerando a rela&ccedil;&atilde;o custo-efic&aacute;cia, &eacute; prov&aacute;vel que a inje&ccedil;&atilde;o de PRP n&atilde;o seja adequada a curto prazo[36]. &nbsp;<br />Nas tendinopatias da coifa dos rotadores os resultados divergem. Como adjuvante &agrave; artroscopia, a aplica&ccedil;&atilde;o de PRP resultou em melhoria funcional e cl&iacute;nica[41, 43-47]. Contudo apenas quatro destes estudos compararam estes resultados com a artroscopia isolada, n&atilde;o evidenciando diferen&ccedil;as na maioria dos par&acirc;metros avaliados[41, 43, 45, 46]. Num destes estudos, a aplica&ccedil;&atilde;o de matrizes de fibrina associou-se a menor taxa de recidivas de rotura[45]; noutro ensaio cl&iacute;nico o PRP mostrou-se clinicamente vantajoso somente nos primeiros seis meses, n&atilde;o existindo diferen&ccedil;as ap&oacute;s dois anos [46]. De acordo com estes resultados, o uso de PRP como adjuvante &agrave; artroscopia n&atilde;o parece ter qualquer impacto[41, 43]. No tratamento da omalgia cr&oacute;nica, as inje&ccedil;&otilde;es de PRP foram eficazes[42]. &nbsp;<br />Relativamente &agrave;s tendinopatias aquilianas, a aplica&ccedil;&atilde;o de PRP nas les&otilde;es agudas associa-se a cicatriza&ccedil;&atilde;o acelerada com recupera&ccedil;&atilde;o funcional precoce[8, 49]. Nas tendinopatias cr&oacute;nicas, a maioria dos estudos n&atilde;o encontrou qualquer benef&iacute;cio a curto ou longo prazo[50-53]; um deles sugerindo uma diminui&ccedil;&atilde;o funcional ap&oacute;s o tratamento com PRP[53]. Apenas um estudo obteve bons resultados, por&eacute;m &eacute; um estudo n&atilde;o comparativo[54]. <br />Nas tendinopatias rotulianas, embora os dados da literatura sejam insuficientes, os resultados dos estudos at&eacute; agora realizados s&atilde;o encorajadores[58, 59]. <br />Apesar da escassez de informa&ccedil;&atilde;o relativamente ao uso de PRP no m&uacute;sculo, a sua aplica&ccedil;&atilde;o nas les&otilde;es agudas obteve bons resultados em todos os estudos encontrados, com recupera&ccedil;&atilde;o acelerada (entre 7 e 17 dias)[13, 24, 33]. A dimens&atilde;o das les&otilde;es pode determinar o protocolo de tratamento, com as roturas maiores necessitando de m&uacute;ltiplas inje&ccedil;&otilde;es[34]. <br />O timing de inje&ccedil;&atilde;o do PRP pode ser importante no tratamento das les&otilde;es agudas. No m&uacute;sculo, a aplica&ccedil;&atilde;o entre o primeiro e o terceiro dias p&oacute;s-lesionais traduziu-se por uma recupera&ccedil;&atilde;o funcional acelerada[13, 33]. Nas les&otilde;es agudas do tend&atilde;o Aquiliano, a administra&ccedil;&atilde;o de PRP nos primeiros cinco dias obteve resultados desanimadores comparativamente aos controlos[53]. J&aacute; o tratamento nas primeiras duas semanas demonstrou um efeito muito superior ao grupo controlo[49]; bem como a administra&ccedil;&atilde;o ap&oacute;s os primeiros seis dias, &agrave; qual se associou uma recupera&ccedil;&atilde;o acelerada[8]. Continua por esclarecer se a aplica&ccedil;&atilde;o destas terapias &eacute; igualmente eficaz no per&iacute;odo agudo ou se &eacute; mais vantajosa ap&oacute;s esta fase. <br />A fenestra&ccedil;&atilde;o dos tend&otilde;es antes da inje&ccedil;&atilde;o pode ter um efeito positivo na cicatriza&ccedil;&atilde;o[12, 42], tendo sido usada por seis estudos[36, 37, 39, 44, 58, 59]. Rha et al compararam a aplica&ccedil;&atilde;o de PRP com a microtenotomia percut&acirc;nea nas tendinopatias do supraespinhoso, verificando efic&aacute;cia por parte de ambas as t&eacute;cnicas, com superioridade do PRP no al&iacute;vio sintom&aacute;tico e na recupera&ccedil;&atilde;o funcional[42]. Esta t&eacute;cnica pode ter um efeito sinerg&iacute;stico ao PRP e ser um fator de confus&atilde;o na avalia&ccedil;&atilde;o dos resultados.<br />Sabe-se que a estimula&ccedil;&atilde;o mec&acirc;nica tamb&eacute;m potencia a repara&ccedil;&atilde;o tendinosa[62]. Segundo Virchenko et al, a carga mec&acirc;nica e o PRP aceleram a cicatriza&ccedil;&atilde;o, atuando de modo independente[62]. Assim, os fatores de crescimento atuam numa fase inicial, sendo posteriormente necess&aacute;rio o aumento da carga mec&acirc;nica para a recupera&ccedil;&atilde;o total[62]. <br />O PRP pode ser uma op&ccedil;&atilde;o nas les&otilde;es refrat&aacute;rias aos tratamentos conservadores, evitando-se procedimentos mais invasivos[60]. Devido aos resultados divergentes n&atilde;o existem recomenda&ccedil;&otilde;es espec&iacute;ficas sobre a sua aplica&ccedil;&atilde;o. O Comit&eacute; Ol&iacute;mpico Internacional aconselha a sua utiliza&ccedil;&atilde;o     cautelosa, at&eacute; que surjam novas evid&ecirc;ncias[15].</p></font>    <p>&nbsp;</p>    <p><b><font face="Verdana" size="2">CONCLUSÃO</font></b></p><font face="verdana" size="2">    <p>&Eacute; poss&iacute;vel que os diferentes resultados observados se devam &agrave; n&atilde;o uniformiza&ccedil;&atilde;o dos protocolos de prepara&ccedil;&atilde;o e aplica&ccedil;&atilde;o. Em estudos futuros &eacute; necess&aacute;rio padronizar alguns par&acirc;metros: o volume, o tipo de prepara&ccedil;&atilde;o, o n&uacute;mero de inje&ccedil;&otilde;es, o timing e dura&ccedil;&atilde;o do tratamento e os protocolos p&oacute;s-inje&ccedil;&atilde;o, de modo a maximizar o seu efeito. <br />Segundo as evid&ecirc;ncias atuais, a aplica&ccedil;&atilde;o de PRP &eacute; eficaz nas epicondiloses; sem benef&iacute;cio nas tendinopatias aquilianas cr&oacute;nicas. Nas tendinopatias da coifa dos rotadores os resultados divergem. Relativamente &agrave;s les&otilde;es musculares e rotulianas, apesar da literatura ser insuficiente, parece existir um efeito cl&iacute;nico e imagiol&oacute;gico positivo do PRP.<br />Os fatores de crescimento constituem uma fam&iacute;lia heterog&eacute;nea possuindo diversas fun&ccedil;&otilde;es, algumas das quais antag&oacute;nicas. No futuro poder&aacute; ponderar-se a terapia dirigida &agrave; les&atilde;o, escolhendo, purificando e conjugando os fatores de crescimento, de acordo com as fun&ccedil;&otilde;es que pretendemos potencializar face &agrave;s necessidades dos <br />tecidos alvo.</p></font>    ]]></body>
<body><![CDATA[<p>&nbsp;</p>    <p><b><font face="Verdana" size="2">REFERÊNCIAS BIBLIOGRÁFICAS</font></b></p>    <!-- ref --><p><font face="verdana" size="2">1. Coombes BK, Bisset L, Vicenzino B. Efficacy and safety of corticosteroid injections and other injections for management of tendinopathy: a systematic review of randomised controlled trials. Lancet. 2010; 376 (9754): 1751-1767</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000065&pid=S1646-2122201300030000300001&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><p><font face="verdana" size="2">2. de Vos  RJ, van Veldhoven  PL, Moen MH, Weir A, Tol JL, Maffulli N. Autologous growth fator injections in chronic tendinopathy: a systematic review. Br Med Bull. 2009;  (95): 63-77</font></p>    <!-- ref --><p><font face="verdana" size="2">3. Sanchez M, Anitua E E, Orive G, Mujika I, Andia I. Platelet-rich therapies in the treatment of orthopaedic sport injuries. Sports Med. 2009; 39 (5): 345-354</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000067&pid=S1646-2122201300030000300003&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">4. Engebretsen L, Steffen  K, Alsousou J, Anitua  E, Bachl N, Devilee R. IOC consensus paper on the use of platelet-rich plasma in sports medicine. Br J Sports Med. 2010; 44 (15): 1072-1081</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000068&pid=S1646-2122201300030000300004&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">5. Mishra A, Woodall J, Vieira A. Treatment of tendon and muscle using platelet-rich plasma. Clin Sports Med. 2009; 28 (1): 113-125</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000069&pid=S1646-2122201300030000300005&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">6. Hayter CL, Adler RS. Injuries of the elbow and the current treatment of tendon disease. AJR Am J Roentgenol. 2012; 199 (3): 285-293</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000070&pid=S1646-2122201300030000300006&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><p><font face="verdana" size="2">7. Anitua E E, Sanchez  M, Nurden AT, Zalduendo M, de la Fuente  M, Orive G. Autologous fibrin matrices: a potential source of biological mediators that modulate tendon cell activities.  J Biomed Mater Res A. 2006; 77 (2): 285-293</font></p>    <!-- ref --><p><font face="verdana" size="2">8. Filardo G, Presti ML, Kon E, Marcacci  M. Nonoperative biological treatment approach for partial Achilles tendon lesion. Orthopedics. 2010; 33 (2): 120-123</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000072&pid=S1646-2122201300030000300008&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">9. Lopez-Vidriero  E, Goulding KA, Simon DA, Sanchez  M, Johnson DH. The use of platelet-rich plasma in arthroscopy and sports medicine: optimizing the healing environment. Arthroscopy. 2010; 26 (2): 269-278</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000073&pid=S1646-2122201300030000300009&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">10. Cole BJ, Seroyer ST, Filardo G, Bajaj  S, Fortier LA. Platelet-rich plasma: where are we now and where are we going? . Sports Health. 2010; 2 (3): 203-210</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000074&pid=S1646-2122201300030000300010&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">11. Garcia VV, Duhrkop  DC, Seijas R, Ares O, Cugat R. Surgical treatment of proximal ruptures of the rectus femoris in professional soccer players. Arch Orthop Trauma Surg. 2012; 132 (3): 329-333</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000075&pid=S1646-2122201300030000300011&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">12. Lee KS, Wilson JJ, Rabago DP, Baer GS, Jacobson JA, Borrero  CG. Musculoskeletal applications of platelet-rich plasma: fad or future. AJR Am J Roentgenol. 2011; 196 (3): 628-636</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000076&pid=S1646-2122201300030000300012&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">13. Wright-Carpenter  T, Klein P, Schaferhoff  P, Appell  HJ, Mir LM, Wehling P. Treatment of muscle injuries by local administration of autologous conditioned serum: a pilot study on sportsmen with muscle strains. Int J Sports Med. 2004; 25 (8): 588-593</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000077&pid=S1646-2122201300030000300013&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">14. Hammond  JW, Hinton RY, Curl LA, Muriel JM, Lovering RM. Use of autologous platelet-rich plasma to treat muscle strain injuries. Am J Sports Med. 2009; 37 (6): 1135-1142</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000078&pid=S1646-2122201300030000300014&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">15. Engebretsen L, Steffen K. To PRP or not. Br J Sports Med. 2010; 44 (15): 1071</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000079&pid=S1646-2122201300030000300015&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><p><font face="verdana" size="2">16. Maffulli N, Del Buono  A. Platelet plasma rich products in musculoskeletal medicine: any evidence. Surgeon. 2012; 10 (3): 148-150</font></p>    <!-- ref --><p><font face="verdana" size="2">17. Cugat  R, Garcia-Balletbo  M. Growth factors - A brief review. European Musculoskeletal Review. 2010; 5 (2): 32-35</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000081&pid=S1646-2122201300030000300017&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">18. Creaney  L, Hamilton B. Growth fator delivery methods in the management of sports injuries: the state of play. Br J Sports Med. 2008; 42 (5): 314-320</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000082&pid=S1646-2122201300030000300018&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">19. Alsousou J, Ali A, Willett K, Harrison P. The role of platelet-rich plasma in tissue regeneration. Platelets. 2012;    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000083&pid=S1646-2122201300030000300019&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> </font></p>    <!-- ref --><p><font face="verdana" size="2">20. Anitua  E, Sanchez  M, Orive  G, Andia I.  The potential impact of the preparation rich in growth factors (PRGF) in different medical fields. Biomaterials. 2007; 28 (31): 4551-4560</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000085&pid=S1646-2122201300030000300020&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">21. Mei-Dan  O, Carmont MR. The role of platelet-rich plasma in rotator cuff repair. Sports Med Arthrosc. 2011; 19 (3): 244-250</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000086&pid=S1646-2122201300030000300021&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><p><font face="verdana" size="2">22. Del Buono  A, Papalia R, Denaro V, Maccauro G, Maffulli N.  Platelet rich plasma and tendinopathy: state of the art. Int J Immunopathol Pharmacol. 2011; 24 (1): 79-83</font></p>    <!-- ref --><p><font face="verdana" size="2">23. Mazzocca AD, McCarthy MB, Chowaniec DM, Dugdale EM, Hansen D, Cote MP. The positive effects of different platelet-rich plasma methods on human muscle, bone, and tendon cells. Am J Sports Med. 2012; 40 (8): 1742-1749</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000088&pid=S1646-2122201300030000300023&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">24. Loo WL, Lee DY, Soon MY. Plasma rich in growth factors to treat adductor longus tear. . Ann Acad Med Singapore. 2009; 38 (8): 733-734</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000089&pid=S1646-2122201300030000300024&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">25. Andia I, Sanchez M, Maffulli N. Joint pathology and platelet-rich plasma therapies.  Expert Opin Biol Ther. 2012; 12 (1): 7-22</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000090&pid=S1646-2122201300030000300025&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">26. van Sterkenburg  MN, van Dijk  CN. Injection treatment for chronic midportion Achilles tendinopathy: do we need that many alternatives. Knee Surg Sports Traumatol Arthrosc. 2011; 19 (4): 513-515</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000091&pid=S1646-2122201300030000300026&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><p><font face="verdana" size="2">27. Dohan Ehrenfest  DM, Rasmusson L, Albrektsson  T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). . Trends Biotechnol. 2009; 27 (3): 158-167</font></p>    ]]></body>
<body><![CDATA[<!-- ref --><p><font face="verdana" size="2">28. Everts PA, Overdevest EP, Jakimowicz JJ, Oosterbos CJ, Schonberger JP, Knape JT.  The use of autologous platelet-leukocyte gels to enhance the healing process in surgery, a review. Surg Endosc. 2007; 21 (11): 2063-2068</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000093&pid=S1646-2122201300030000300028&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><p><font face="verdana" size="2">29. Practical guidelines for using PRP in the orthopaedic office[homepage on the Internet]. Rosemont: AAOS.org; 09/2010 ; cited 2012 Sep 10]. Available from: <a href="http://www.aaos.org/news/aaosnow/sep10/clinical3.asp" target="_blank">http://www.aaos.org/news/aaosnow/sep10/clinical3.asp</a>.</font></p>    <!-- ref --><p><font face="verdana" size="2">30. Muto T, Kokubu T, Mifune Y, Sakata R, Nagura I, Nishimoto H. Platelet-rich plasma protects rotator cuff-derived cells from the deleterious effects of triamcinolone acetonide.  J Orthop Res. 2012.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000095&pid=S1646-2122201300030000300030&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> 2012; </font></p>    <!-- ref --><p><font face="verdana" size="2">31. Anitua  E, Sanchez  M. We cannot take oranges for apples in the field of platelet-rich plasma products. Scand J Med Sci Sports. 2012; 22 (2): 147-148</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000097&pid=S1646-2122201300030000300031&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">32. Alsousou J, Thompson M, Hulley  P, Noble A, Willett K. The biology of platelet-rich plasma and its application in trauma and orthopaedic surgery: a review of the literature. J Bone Joint Surg Br. 2009; 91 (8): 987-996</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000098&pid=S1646-2122201300030000300032&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">33. Hamilton B, Knez W, Eirale C, Chalabi H. . Platelet enriched plasma for acute muscle injury. Ata Orthop Belg. 2010; 76 (4): 1774-1778</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000099&pid=S1646-2122201300030000300033&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">34. Andia I, Sanchez M, Maffulli N.  Platelet rich plasma therapies for sports muscle injuries: any evidence behind clinical practice. Expert Opin Biol Ther. 2011; 11 (4): 509-518</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000100&pid=S1646-2122201300030000300034&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">35. Mishra A, Pavelko T.  Treatment of chronic elbow tendinosis with buffered platelet-rich plasma. Am J Sports Med. 2006; 34 (11): 1774-1778</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000101&pid=S1646-2122201300030000300035&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">36. Peerbooms JC, Sluimer J, Bruijn DJ, Gosens T. Positive effect of an autologous platelet concentrate in lateral epicondylitis in a double-blind randomized controlled trial: platelet-rich plasma versus corticosteroid injection with a 1-year follow-up. Am J Sports Med. 2010; 38 (2): 255-262</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000102&pid=S1646-2122201300030000300036&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><p><font face="verdana" size="2">37. Gosens  T, Peerbooms JC, van Laar  W, den Oudsten  BL.  Ongoing positive effect of platelet-rich plasma versus corticosteroid injection in lateral epicondylitis: a double-blind randomized controlled trial with 2-year follow-up. . Am J Sports Med. 2011; 39 (6): 1200-1208</font></p>    <!-- ref --><p><font face="verdana" size="2">38. Creaney  L, Wallace A, Curtis  M, Connell D.  Growth fator-based therapies provide additional benefit beyond physical therapy in resistant elbow tendinopathy: a prospective, single-blind, randomised trial of autologous blood injections versus platelet-rich plasma injections. . Br J Sports Med. 2011; 45 (12): 966-971</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000104&pid=S1646-2122201300030000300038&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><p><font face="verdana" size="2">39. Chaudhury S, de La Lama  M, Adler RS, Gulotta LV.  Platelet-rich plasma for the treatment of lateral epicondylitis: sonographic assessment of tendon morphology and vascularity (pilot study). Skeletal Radiol. 2012; </font></p>    <!-- ref --><p><font face="verdana" size="2">40. Thanasas C, Papadimitriou G, Charalambidis C, Paraskevopoulos I, Papanikolaou A. Platelet-rich plasma versus autologous whole blood for the treatment of chronic lateral elbow epicondylitis: a randomized controlled clinical trial. Am J Sports Med. 2011; 39 (10): 2130-2134</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000106&pid=S1646-2122201300030000300040&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><p><font face="verdana" size="2">41. Castricini R, Longo UG, De Benedetto  M, Panfoli N, Pirani P, Zini R. Platelet-rich plasma augmentation for arthroscopic rotator cuff repair: a randomized controlled trial.  Am J Sports Med. 2011; 39 (2): 258-265</font></p>    <!-- ref --><p><font face="verdana" size="2">42. Rha  DW, Park GY, Kim YK, Kim MT, Lee SC. Comparison of the therapeutic effects of ultrasound-guided platelet-rich plasma injection and dry needling in rotator cuff disease: a randomized controlled trial. . Clin Rehabil. 2012;    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000108&pid=S1646-2122201300030000300042&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> </font></p>    <!-- ref --><p><font face="verdana" size="2">43. Jo CH, Kim JE, Yoon KS, Lee JH, Kang SB, Han HS. Does platelet-rich plasma accelerate recovery after rotator cuff repair. Am J Sports Med. 2011; 39 (10): 2082-2090</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000110&pid=S1646-2122201300030000300043&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">44. Randelli PS, Arrigoni P, Cabitza  P, Volpi P, Maffulli N. Autologous platelet rich plasma for arthroscopic rotator cuff repair. A pilot study. Disabil Rehabil. 2008; 30 (20): 1584-1589</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000111&pid=S1646-2122201300030000300044&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">45. Barber FA, Hrnack SA, Snyder SJ, Hapa O. Rotator cuff repair healing influenced by platelet-rich plasma construct augmentation. Arthroscopy.. 2011; 27 (8): 1029-1035</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000112&pid=S1646-2122201300030000300045&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">46. Randelli P, Arrigoni P, Ragone V, Aliprandi A, Cabitza P. Platelet rich plasma in arthroscopic rotator cuff repair: a prospective RCT study, 2-year follow-up. . J Shoulder Elbow Surg. 2011; 20 (4): 518-528</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000113&pid=S1646-2122201300030000300046&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><p><font face="verdana" size="2">47. Maniscalco P, Gambera D, Lunati A, Vox G, Fossombroni V, Beretta R.  et al. The "Cascade" membrane: a new PRP device for tendon ruptures. Description and case report on rotator cuff tendon. . Ata Biomed. 2008; 79 (3): 223-226</font></p>    <!-- ref --><p><font face="verdana" size="2">48. Seijas R, Ares O, Alvarez P, Cusco X, Garcia-Balletbo  M, Cugat R. Platelet-rich plasma for calcific tendinitis of the shoulder: a case report. J Orthop Surg (Hong Kong). 2012; 20 (1): 126-130</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000115&pid=S1646-2122201300030000300048&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">49. Sanchez  M, Anitua E, Azofra J, Andia I, Padilla S, Mujika I. Comparison of surgically repaired Achilles tendon tears using platelet-rich fibrin matrices. Am J Sports Med. 2007; 35 (2): 245-251</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000116&pid=S1646-2122201300030000300049&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><p><font face="verdana" size="2">50. de Vos  RJ, Weir A, van Schie  HT, Bierma-Zeinstra  SM, Verhaar JA, Weinans H. Platelet-rich plasma injection for chronic Achilles tendinopathy: a randomized controlled trial. JAMA. 2010; 303 (2): 144-149</font></p>    <p><font face="verdana" size="2">51. de Vos  RJ, Weir  A, Tol JL, Verhaar JA, Weinans  H, van Schie  HT.  No effects of PRP on ultrasonographic tendon structure and neovascularisation in chronic midportion Achilles tendinopathy. Br J Sports Med. 2011; 45 (5): 387-392</font></p>    <p><font face="verdana" size="2">52. de Jonge  S, de Vos  RJ, Weir a, van Schie  HT, Bierma-Zeinstra  SM, Verhaar  JA. One-year follow-up of platelet-rich plasma treatment in chronic Achilles tendinopathy: a double-blind randomized placebo-controlled trial. Am J Sports Med. 2011; 39 (8): 1623-1629</font></p>    <!-- ref --><p><font face="verdana" size="2">53. Schepull P, Kvist J, Norrman H, Trinks M, Berlin G, Aspenberg P. Autologous platelets have no effect on the healing of human achilles tendon ruptures: a randomized single-blind study.  Am J Sports Med. 2011; 39 (1): 38-47</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000120&pid=S1646-2122201300030000300053&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">54. Lopez-Gavito  E, Gomez-Carlin  LA, Parra-Tellez  P, Vazquez-Escamilla  J. [Platelet-rich plasma for managing calcaneus tendon tendinopathy and plantar fasciitis]. Ata Ortop Mex. 2011; 25 (6): 380-385</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000121&pid=S1646-2122201300030000300054&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><p><font face="verdana" size="2">55. Sanchez  M, Anitua  E, Cole  A, Da Silva  A, Azofra J, Andia I. Management of post-surgical Achilles tendon complications with a preparation rich in growth factors: A study of two-cases.  Injury Extra. 2009; 40 (1): 11-15</font></p>    ]]></body>
<body><![CDATA[<p><font face="verdana" size="2">56. de Almeida  AM, Demange MK, Sobrado MF, Rodrigues MB, Pedrinelli A, Hernandez AJ. Patellar tendon healing with platelet-rich plasma: a prospective randomized controlled trial. Am J Sports Med. . 2012; 40 (6): 1282-1288</font></p>    <p><font face="verdana" size="2">57. Cervellin  M, de Girolamo  L, Bait C, Denti M, Volpi P. Autologous platelet-rich plasma gel to reduce donor-site morbidity after patellar tendon graft harvesting for anterior cruciate ligament reconstruction: a randomized, controlled clinical study. Knee Surg Sports Traumatol Arthrosc. Knee Surg Sports Traumatol Arthrosc. 2012; 40 (6): 114-120</font></p>    <!-- ref --><p><font face="verdana" size="2">58. Kon E, Filardo G, Delcogliano M, Presti ML, Russo A, Bondi A.  Platelet-rich plasma: new clinical application: a pilot study for treatment of jumper's knee. Injury. 2009; 40 (6): 598-603</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000125&pid=S1646-2122201300030000300058&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><p><font face="verdana" size="2">59. Filardo G, Kon E, Della Villa  S, Vincentelli F, Fornasari PM, Marcacci M. Use of platelet-rich plasma for the treatment of refractory jumper's knee. Int Orthop. 2010; 34 (6): 909-915</font></p>    <p><font face="verdana" size="2">60. Paoloni J, De Vos  RJ, Hamilton B, Murrell GA, Orchard  J. Platelet-rich plasma treatment for ligament and tendon injuries. Clin J Sport Med. 2011; 21 (1): 1</font></p>    <p>&nbsp;</p>    <p><b><font face="Verdana" size="2">Conflito de interesse: </font></b></p><font face="verdana" size="2">    <p>Nada a declarar.</p></font>    <p>&nbsp;</p><a name="c"></a>    <p><b><font face="Verdana" size="2"><a href="#topc">Endereço para correspondência</a></font></b></p>    ]]></body>
<body><![CDATA[<p><font face="Verdana" size="2">Ana Ferrão    <br>Faculdade de Medicina da Universidade    <br>do Porto    <br>Al. Prof. Hernâni Monteiro    <br>4200 - 319 Porto    <br>Portugal    <br><a href="mailto:anamoreiraferrao@gmail.com">anamoreiraferrao@gmail.com</a></font></p>    <p>&nbsp;</p>    <p><font face="verdana" size="2"><b>Data de Submissão: </b> 2013-05-08</font></p>    <p><font face="verdana" size="2"><b>Data de Revisão: </b> 2013-09-15</font></p>    ]]></body>
<body><![CDATA[<p><font face="verdana" size="2"><b>Data de Aceitação: </b> 2013-09-15</font></p>     ]]></body><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Coombes]]></surname>
<given-names><![CDATA[BK]]></given-names>
</name>
<name>
<surname><![CDATA[Bisset]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Vicenzino]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Efficacy and safety of corticosteroid injections and other injections for management of tendinopathy: a systematic review of randomised controlled trials]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2010</year>
<volume>376</volume>
<numero>9754</numero>
<issue>9754</issue>
<page-range>1751-1767</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vos]]></surname>
<given-names><![CDATA[RJ de]]></given-names>
</name>
<name>
<surname><![CDATA[van Veldhoven]]></surname>
<given-names><![CDATA[PL]]></given-names>
</name>
<name>
<surname><![CDATA[Moen]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Weir]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tol]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Maffulli]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Autologous growth fator injections in chronic tendinopathy: a systematic review]]></article-title>
<source><![CDATA[Br Med Bull]]></source>
<year>2009</year>
<numero>95</numero>
<issue>95</issue>
<page-range>63-77</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sanchez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Anitua]]></surname>
<given-names><![CDATA[E E]]></given-names>
</name>
<name>
<surname><![CDATA[Orive]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Mujika]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Andia]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Platelet-rich therapies in the treatment of orthopaedic sport injuries]]></article-title>
<source><![CDATA[Sports Med]]></source>
<year>2009</year>
<volume>39</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>345-354</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Engebretsen]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Steffen]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Alsousou]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Anitua]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bachl]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Devilee]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[IOC consensus paper on the use of platelet-rich plasma in sports medicine]]></article-title>
<source><![CDATA[Br J Sports Med]]></source>
<year>2010</year>
<volume>44</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>1072-1081</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mishra]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Woodall]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Vieira]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Treatment of tendon and muscle using platelet-rich plasma]]></article-title>
<source><![CDATA[Clin Sports Med]]></source>
<year>2009</year>
<volume>28</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>113-125</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hayter]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Adler]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Injuries of the elbow and the current treatment of tendon disease]]></article-title>
<source><![CDATA[AJR Am J Roentgenol]]></source>
<year>2012</year>
<volume>199</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>285-293</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anitua E]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Sanchez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Nurden]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
<name>
<surname><![CDATA[Zalduendo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fuente]]></surname>
<given-names><![CDATA[M de la]]></given-names>
</name>
<name>
<surname><![CDATA[Orive]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Autologous fibrin matrices: a potential source of biological mediators that modulate tendon cell activities]]></article-title>
<source><![CDATA[J Biomed Mater Res A]]></source>
<year>2006</year>
<volume>77</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>285-293</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Filardo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Presti]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Kon]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Marcacci]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Nonoperative biological treatment approach for partial Achilles tendon lesion]]></article-title>
<source><![CDATA[Orthopedics]]></source>
<year>2010</year>
<volume>33</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>120-123</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lopez-Vidriero]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Goulding]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Simon]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Sanchez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The use of platelet-rich plasma in arthroscopy and sports medicine: optimizing the healing environment]]></article-title>
<source><![CDATA[Arthroscopy]]></source>
<year>2010</year>
<volume>26</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>269-278</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cole]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Seroyer]]></surname>
<given-names><![CDATA[ST]]></given-names>
</name>
<name>
<surname><![CDATA[Filardo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Bajaj]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Fortier]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Platelet-rich plasma: where are we now and where are we going?]]></article-title>
<source><![CDATA[Sports Health]]></source>
<year>2010</year>
<volume>2</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>203-210</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garcia]]></surname>
<given-names><![CDATA[VV]]></given-names>
</name>
<name>
<surname><![CDATA[Duhrkop]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Seijas]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ares]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Cugat]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Surgical treatment of proximal ruptures of the rectus femoris in professional soccer players]]></article-title>
<source><![CDATA[Arch Orthop Trauma Surg]]></source>
<year>2012</year>
<volume>132</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>329-333</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Rabago]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
<name>
<surname><![CDATA[Baer]]></surname>
<given-names><![CDATA[GS]]></given-names>
</name>
<name>
<surname><![CDATA[Jacobson]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Borrero]]></surname>
<given-names><![CDATA[CG]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Musculoskeletal applications of platelet-rich plasma: fad or future]]></article-title>
<source><![CDATA[AJR Am J Roentgenol]]></source>
<year>2011</year>
<volume>196</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>628-636</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wright-Carpenter]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Klein]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Schaferhoff]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Appell]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Mir]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Wehling]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Treatment of muscle injuries by local administration of autologous conditioned serum: a pilot study on sportsmen with muscle strains]]></article-title>
<source><![CDATA[Int J Sports Med]]></source>
<year>2004</year>
<volume>25</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>588-593</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hammond]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Hinton]]></surname>
<given-names><![CDATA[RY]]></given-names>
</name>
<name>
<surname><![CDATA[Curl]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Muriel]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Lovering]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Use of autologous platelet-rich plasma to treat muscle strain injuries]]></article-title>
<source><![CDATA[Am J Sports Med]]></source>
<year>2009</year>
<volume>37</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1135-1142</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Engebretsen]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Steffen]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[To PRP or not]]></article-title>
<source><![CDATA[Br J Sports Med]]></source>
<year>2010</year>
<volume>44</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>1071</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maffulli]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Buono]]></surname>
<given-names><![CDATA[A Del]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Platelet plasma rich products in musculoskeletal medicine: any evidence]]></article-title>
<source><![CDATA[Surgeon]]></source>
<year>2012</year>
<volume>10</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>148-150</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cugat]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia-Balletbo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Growth factors: A brief review]]></article-title>
<source><![CDATA[European Musculoskeletal Review]]></source>
<year>2010</year>
<volume>5</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>32-35</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Creaney]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Hamilton]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Growth fator delivery methods in the management of sports injuries: the state of play]]></article-title>
<source><![CDATA[Br J Sports Med]]></source>
<year>2008</year>
<volume>42</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>314-320</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alsousou]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ali]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Willett]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Harrison]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The role of platelet-rich plasma in tissue regeneration]]></article-title>
<source><![CDATA[Platelets]]></source>
<year>2012</year>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anitua]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Sanchez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Orive]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Andia]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The potential impact of the preparation rich in growth factors (PRGF) in different medical fields]]></article-title>
<source><![CDATA[Biomaterials]]></source>
<year>2007</year>
<volume>28</volume>
<numero>31</numero>
<issue>31</issue>
<page-range>4551-4560</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mei-Dan]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Carmont]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The role of platelet-rich plasma in rotator cuff repair]]></article-title>
<source><![CDATA[Sports Med Arthrosc]]></source>
<year>2011</year>
<volume>19</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>244-250</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Buono]]></surname>
<given-names><![CDATA[A Del]]></given-names>
</name>
<name>
<surname><![CDATA[Papalia]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Denaro]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Maccauro]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Maffulli]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Platelet rich plasma and tendinopathy: state of the art]]></article-title>
<source><![CDATA[Int J Immunopathol Pharmacol]]></source>
<year>2011</year>
<volume>24</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>79-83</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mazzocca]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[McCarthy]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Chowaniec]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Dugdale]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Hansen]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Cote]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The positive effects of different platelet-rich plasma methods on human muscle, bone, and tendon cells]]></article-title>
<source><![CDATA[Am J Sports Med]]></source>
<year>2012</year>
<volume>40</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1742-1749</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Loo]]></surname>
<given-names><![CDATA[WL]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[DY]]></given-names>
</name>
<name>
<surname><![CDATA[Soon]]></surname>
<given-names><![CDATA[MY]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Plasma rich in growth factors to treat adductor longus tear.]]></article-title>
<source><![CDATA[Ann Acad Med Singapore]]></source>
<year>2009</year>
<volume>38</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>733-734</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Andia]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Sanchez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Maffulli]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Joint pathology and platelet-rich plasma therapies]]></article-title>
<source><![CDATA[Expert Opin Biol Ther]]></source>
<year>2012</year>
<volume>12</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>7-22</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[van Sterkenburg]]></surname>
<given-names><![CDATA[MN]]></given-names>
</name>
<name>
<surname><![CDATA[van Dijk]]></surname>
<given-names><![CDATA[CN]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Injection treatment for chronic midportion Achilles tendinopathy: do we need that many alternatives]]></article-title>
<source><![CDATA[Knee Surg Sports Traumatol Arthrosc]]></source>
<year>2011</year>
<volume>19</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>513-515</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ehrenfest]]></surname>
<given-names><![CDATA[DM Dohan]]></given-names>
</name>
<name>
<surname><![CDATA[Rasmusson]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Albrektsson]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP to leucocyte and platelet-rich fibrin (L-PRF).]]></article-title>
<source><![CDATA[Trends Biotechnol]]></source>
<year>2009</year>
<volume>27</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>158-167</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Everts]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Overdevest]]></surname>
<given-names><![CDATA[EP]]></given-names>
</name>
<name>
<surname><![CDATA[Jakimowicz]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Oosterbos]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Schonberger]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Knape]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The use of autologous platelet-leukocyte gels to enhance the healing process in surgery, a review]]></article-title>
<source><![CDATA[Surg Endosc]]></source>
<year>2007</year>
<volume>21</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>2063-2068</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="">
<source><![CDATA[Practical guidelines for using PRP in the orthopaedic office]]></source>
<year>09/2</year>
<month>01</month>
<day>0</day>
<edition>AAOS.org</edition>
<publisher-loc><![CDATA[Rosemont ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muto]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Kokubu]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Mifune]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Sakata]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Nagura]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Nishimoto]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Platelet-rich plasma protects rotator cuff-derived cells from the deleterious effects of triamcinolone acetonide]]></article-title>
<source><![CDATA[J Orthop Res]]></source>
<year>2012</year>
</nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anitua]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Sanchez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[We cannot take oranges for apples in the field of platelet-rich plasma products]]></article-title>
<source><![CDATA[Scand J Med Sci Sports]]></source>
<year>2012</year>
<volume>22</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>147-148</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alsousou]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Thompson]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hulley]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Noble]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Willett]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The biology of platelet-rich plasma and its application in trauma and orthopaedic surgery: a review of the literature]]></article-title>
<source><![CDATA[J Bone Joint Surg Br]]></source>
<year>2009</year>
<volume>91</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>987-996</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hamilton]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Knez]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Eirale]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Chalabi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[: Platelet enriched plasma for acute muscle injury]]></article-title>
<source><![CDATA[Ata Orthop Belg]]></source>
<year>2010</year>
<volume>76</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1774-1778</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Andia]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Sanchez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Maffulli]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Platelet rich plasma therapies for sports muscle injuries: any evidence behind clinical practice]]></article-title>
<source><![CDATA[Expert Opin Biol Ther]]></source>
<year>2011</year>
<volume>11</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>509-518</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mishra]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pavelko]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Treatment of chronic elbow tendinosis with buffered platelet-rich plasma]]></article-title>
<source><![CDATA[Am J Sports Med]]></source>
<year>2006</year>
<volume>34</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1774-1778</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peerbooms]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Sluimer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bruijn]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Gosens]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Positive effect of an autologous platelet concentrate in lateral epicondylitis in a double-blind randomized controlled trial: platelet-rich plasma versus corticosteroid injection with a 1-year follow-up]]></article-title>
<source><![CDATA[Am J Sports Med]]></source>
<year>2010</year>
<volume>38</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>255-262</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gosens]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Peerbooms]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[van Laar]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Oudsten]]></surname>
<given-names><![CDATA[BL den]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Ongoing positive effect of platelet-rich plasma versus corticosteroid injection in lateral epicondylitis: a double-blind randomized controlled trial with 2-year follow-up.]]></article-title>
<source><![CDATA[Am J Sports Med]]></source>
<year>2011</year>
<volume>39</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1200-1208</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Creaney]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Wallace]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Curtis]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Connell]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Growth fator-based therapies provide additional benefit beyond physical therapy in resistant elbow tendinopathy: a prospective single-blind randomised trial of autologous blood injections versus platelet-rich plasma injections.]]></article-title>
<source><![CDATA[Br J Sports Med]]></source>
<year>2011</year>
<volume>45</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>966-971</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chaudhury]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lama]]></surname>
<given-names><![CDATA[M de La]]></given-names>
</name>
<name>
<surname><![CDATA[Adler]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Gulotta]]></surname>
<given-names><![CDATA[LV]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Platelet-rich plasma for the treatment of lateral epicondylitis: sonographic assessment of tendon morphology and vascularity (pilot study)]]></article-title>
<source><![CDATA[Skeletal Radiol]]></source>
<year>2012</year>
</nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thanasas]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Papadimitriou]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Charalambidis]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Paraskevopoulos]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Papanikolaou]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Platelet-rich plasma versus autologous whole blood for the treatment of chronic lateral elbow epicondylitis: a randomized controlled clinical trial]]></article-title>
<source><![CDATA[Am J Sports Med]]></source>
<year>2011</year>
<volume>39</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>2130-2134</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castricini]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Longo]]></surname>
<given-names><![CDATA[UG]]></given-names>
</name>
<name>
<surname><![CDATA[Benedetto]]></surname>
<given-names><![CDATA[M De]]></given-names>
</name>
<name>
<surname><![CDATA[Panfoli]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Pirani]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Zini]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Platelet-rich plasma augmentation for arthroscopic rotator cuff repair: a randomized controlled trial]]></article-title>
<source><![CDATA[Am J Sports Med]]></source>
<year>2011</year>
<volume>39</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>258-265</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rha]]></surname>
<given-names><![CDATA[DW]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[GY]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[YK]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Comparison of the therapeutic effects of ultrasound-guided platelet-rich plasma injection and dry needling in rotator cuff disease: a randomized controlled trial.]]></article-title>
<source><![CDATA[Clin Rehabil]]></source>
<year>2012</year>
</nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jo]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Yoon]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Kang]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
<name>
<surname><![CDATA[Han]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Does platelet-rich plasma accelerate recovery after rotator cuff repair]]></article-title>
<source><![CDATA[Am J Sports Med]]></source>
<year>2011</year>
<volume>39</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>2082-2090</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Randelli]]></surname>
<given-names><![CDATA[PS]]></given-names>
</name>
<name>
<surname><![CDATA[Arrigoni]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Cabitza]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Volpi]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Maffulli]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Autologous platelet rich plasma for arthroscopic rotator cuff repair: A pilot study]]></article-title>
<source><![CDATA[Disabil Rehabil]]></source>
<year>2008</year>
<volume>30</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>1584-1589</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barber]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
<name>
<surname><![CDATA[Hrnack]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Snyder]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hapa]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Rotator cuff repair healing influenced by platelet-rich plasma construct augmentation]]></article-title>
<source><![CDATA[Arthroscopy]]></source>
<year>2011</year>
<volume>27</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1029-1035</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Randelli]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Arrigoni]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Ragone]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Aliprandi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cabitza]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Platelet rich plasma in arthroscopic rotator cuff repair: a prospective RCT study 2-year follow-up.]]></article-title>
<source><![CDATA[J Shoulder Elbow Surg]]></source>
<year>2011</year>
<volume>20</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>518-528</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maniscalco]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Gambera]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Lunati]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Vox]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Fossombroni]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Beretta]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The “Cascade” membrane a new PRP device for tendon ruptures Description and case report on rotator cuff tendon]]></article-title>
<source><![CDATA[Ata Biomed]]></source>
<year>2008</year>
<volume>79</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>223-226</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Seijas]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ares]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Alvarez]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Cusco]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia-Balletbo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cugat]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Platelet-rich plasma for calcific tendinitis of the shoulder: a case report]]></article-title>
<source><![CDATA[J Orthop Surg (Hong Kong)]]></source>
<year>2012</year>
<volume>20</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>126-130</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sanchez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Anitua]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Azofra]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Andia]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Padilla]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mujika]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Comparison of surgically repaired Achilles tendon tears using platelet-rich fibrin matrices]]></article-title>
<source><![CDATA[Am J Sports Med]]></source>
<year>2007</year>
<volume>35</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>245-251</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vos]]></surname>
<given-names><![CDATA[RJ de]]></given-names>
</name>
<name>
<surname><![CDATA[Weir]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[van Schie]]></surname>
<given-names><![CDATA[HT]]></given-names>
</name>
<name>
<surname><![CDATA[Bierma-Zeinstra]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Verhaar]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Weinans]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Platelet-rich plasma injection for chronic Achilles tendinopathy: a randomized controlled trial]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2010</year>
<volume>303</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>144-149</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vos]]></surname>
<given-names><![CDATA[RJ de]]></given-names>
</name>
<name>
<surname><![CDATA[Weir]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tol]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Verhaar]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Weinans]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[van Schie]]></surname>
<given-names><![CDATA[HT]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[No effects of PRP on ultrasonographic tendon structure and neovascularisation in chronic midportion Achilles tendinopathy]]></article-title>
<source><![CDATA[Br J Sports Med]]></source>
<year>2011</year>
<volume>45</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>387-392</page-range></nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jonge]]></surname>
<given-names><![CDATA[S de]]></given-names>
</name>
<name>
<surname><![CDATA[de Vos]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Weir]]></surname>
<given-names><![CDATA[a]]></given-names>
</name>
<name>
<surname><![CDATA[van Schie]]></surname>
<given-names><![CDATA[HT]]></given-names>
</name>
<name>
<surname><![CDATA[Bierma-Zeinstra]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Verhaar]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[One-year follow-up of platelet-rich plasma treatment in chronic Achilles tendinopathy: a double-blind randomized placebo-controlled trial]]></article-title>
<source><![CDATA[Am J Sports Med]]></source>
<year>2011</year>
<volume>39</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1623-1629</page-range></nlm-citation>
</ref>
<ref id="B53">
<label>53</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schepull]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Kvist]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Norrman]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Trinks]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Berlin]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Aspenberg]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Autologous platelets have no effect on the healing of human achilles tendon ruptures: a randomized single-blind study]]></article-title>
<source><![CDATA[Am J Sports Med]]></source>
<year>2011</year>
<volume>39</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>38-47</page-range></nlm-citation>
</ref>
<ref id="B54">
<label>54</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lopez-Gavito]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Gomez-Carlin]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Parra-Tellez]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Vazquez-Escamilla]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[[Platelet-rich plasma for managing calcaneus tendon tendinopathy and plantar fasciitis]]]></article-title>
<source><![CDATA[Ata Ortop Mex]]></source>
<year>2011</year>
<volume>25</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>380-385</page-range></nlm-citation>
</ref>
<ref id="B55">
<label>55</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sanchez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Anitua]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Cole]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[A Da]]></given-names>
</name>
<name>
<surname><![CDATA[Azofra]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Andia]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Management of post-surgical Achilles tendon complications with a preparation rich in growth factors: A study of two-cases]]></article-title>
<source><![CDATA[Injury Extra]]></source>
<year>2009</year>
<volume>40</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>11-15</page-range></nlm-citation>
</ref>
<ref id="B56">
<label>56</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Almeida]]></surname>
<given-names><![CDATA[AM de]]></given-names>
</name>
<name>
<surname><![CDATA[Demange]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
<name>
<surname><![CDATA[Sobrado]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Rodrigues]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Pedrinelli]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hernandez]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Patellar tendon healing with platelet-rich plasma: a prospective randomized controlled trial]]></article-title>
<source><![CDATA[Am J Sports Med.]]></source>
<year>2012</year>
<volume>40</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1282-1288</page-range></nlm-citation>
</ref>
<ref id="B57">
<label>57</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cervellin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Girolamo]]></surname>
<given-names><![CDATA[L de]]></given-names>
</name>
<name>
<surname><![CDATA[Bait]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Denti]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Volpi]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Autologous platelet-rich plasma gel to reduce donor-site morbidity after patellar tendon graft harvesting for anterior cruciate ligament reconstruction: a randomized controlled clinical study Knee Surg Sports Traumatol Arthrosc]]></article-title>
<source><![CDATA[Knee Surg Sports Traumatol Arthrosc]]></source>
<year>2012</year>
<volume>40</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>114-120</page-range></nlm-citation>
</ref>
<ref id="B58">
<label>58</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kon]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Filardo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Delcogliano]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Presti]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Russo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bondi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Platelet-rich plasma: new clinical application a pilot study for treatment of jumper's knee]]></article-title>
<source><![CDATA[Injury]]></source>
<year>2009</year>
<volume>40</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>598-603</page-range></nlm-citation>
</ref>
<ref id="B59">
<label>59</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Filardo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Kon]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Villa]]></surname>
<given-names><![CDATA[S Della]]></given-names>
</name>
<name>
<surname><![CDATA[Vincentelli]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Fornasari]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Marcacci]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Use of platelet-rich plasma for the treatment of refractory jumper's knee]]></article-title>
<source><![CDATA[Int Orthop]]></source>
<year>2010</year>
<volume>34</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>909-915</page-range></nlm-citation>
</ref>
<ref id="B60">
<label>60</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Paoloni]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Vos]]></surname>
<given-names><![CDATA[RJ De]]></given-names>
</name>
<name>
<surname><![CDATA[Hamilton]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Murrell]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Orchard]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Platelet-rich plasma treatment for ligament and tendon injuries]]></article-title>
<source><![CDATA[Clin J Sport Med]]></source>
<year>2011</year>
<volume>21</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
